The European Medicines Agency (EMA) has recommended refusal of a marketing authorization for donanemab, which targets the treatment of early Alzheimer’s disease (AD). The agency’s Committee for Medicinal Products for Human Use said that the benefits of the medicine were not sufficient to outweigh the risk of potentially fatal events…
Leave a Comment Leave a Comment
